N4 Pharma (N4P)

Sector:

Pharma and Biotech

Index:

FTSE AIM All-Share

 0.83p
   
  • Change Today:
      0.000p
  • 52 Week High: 3.07
  • 52 Week Low: 0.80
  • Currency: UK Pounds
  • Shares Issued: 268.78m
  • Volume: 0
  • Market Cap: £2.22m

Growth Ratings

EPS Growth shows the relative growth of a company's earnings over the last year.

The rise in total monies receivable for goods / services sold before expenses.

1yr EPS Growth Not Available
1yr Revenue Growth Not Available

Income Ratings

The percentage of the share price that a company pays out as dividends over a year.

The percentage change from the previous year in the dividend paid on each share.

Dividend Yield Not Available
1yr DPS Growth Not Available

Valuation Ratings

The share price as a ratio of revenue per share.

The share price as a ratio of net asset value.

Price Sales Ratio
98.46% above the market average98.46% above the market average98.46% above the market average98.46% above the market average98.46% above the market average
100.00% above the sector average100.00% above the sector average100.00% above the sector average100.00% above the sector average100.00% above the sector average
Price Book Ratio
42.22% below the market average42.22% below the market average42.22% below the market average42.22% below the market average42.22% below the market average
10.20% above the sector average10.20% above the sector average10.20% above the sector average10.20% above the sector average10.20% above the sector average

Performance Ratings

In percentage total change in share price over 30 days.

In percentage total change in share price over 3 months.

Price Chg 30d
87.65% above the market average87.65% above the market average87.65% above the market average87.65% above the market average87.65% above the market average
85.96% above the sector average85.96% above the sector average85.96% above the sector average85.96% above the sector average85.96% above the sector average
Price Chg 3m
52.73% below the market average52.73% below the market average52.73% below the market average52.73% below the market average52.73% below the market average
12.28% above the sector average12.28% above the sector average12.28% above the sector average12.28% above the sector average12.28% above the sector average

Technical Ratings

The Relative Strength Index measures a share price relative to itself and its recent history.

Momentum is an oscillator that measures the rate of price change.

RSI Not Available
Momentum 20 Not Available

Management Ratings

Operating Margin is profit as a percentage of sales.

Return on capital employed measures the return from invested and borrowed capital.

Operating Margin
99.53% below the market average99.53% below the market average99.53% below the market average99.53% below the market average99.53% below the market average
100% below the sector average100% below the sector average100% below the sector average100% below the sector average100% below the sector average
ROCE Not Available

Profitability Ratings

Earnings per share, the company's profitability expressed on a per share basis.

Analysts' estimates of future EPS for the next 2 years.

EPS
43.45% below the market average43.45% below the market average43.45% below the market average43.45% below the market average43.45% below the market average
29.63% above the sector average29.63% above the sector average29.63% above the sector average29.63% above the sector average29.63% above the sector average
Forecast EPS Not Available

Profit/Loss Ratings

Monies produced from sales of goods and services after trade discounts, VAT, etc.

Operating Profit is the profit after deducting operating costs from gross profits.

Turnover
98.59% below the market average98.59% below the market average98.59% below the market average98.59% below the market average98.59% below the market average
94.59% below the sector average94.59% below the sector average94.59% below the sector average94.59% below the sector average94.59% below the sector average
Operating Profit Loss
45.22% below the market average45.22% below the market average45.22% below the market average45.22% below the market average45.22% below the market average
40.74% above the sector average40.74% above the sector average40.74% above the sector average40.74% above the sector average40.74% above the sector average

Balance Sheet Ratings

The difference between current assets and current liabilities.

A current asset representing the company's financial liquidity.

Assets
83.07% below the market average83.07% below the market average83.07% below the market average83.07% below the market average83.07% below the market average
88.68% below the sector average88.68% below the sector average88.68% below the sector average88.68% below the sector average88.68% below the sector average
Cash
62.24% below the market average62.24% below the market average62.24% below the market average62.24% below the market average62.24% below the market average
77.78% below the sector average77.78% below the sector average77.78% below the sector average77.78% below the sector average77.78% below the sector average

Director Deal Ratings

The cumulative amount of stocks sold by company directors over 1 year

The cumulative amount of stocks bought by company directors over 1 year

Sells 1y Not Available
Buys 1y Not Available

Broker Ratings

The percentage of stockbrokers that rate the company as a Buy

The percentage of stockbrokers that rate the company as a Hold

Brokers Percent Buy Not Available
Brokers Percent Neutral Not Available

Note 1: Prices and trades are provided by Digital Look Corporate Solutions and are delayed by at least 15 minutes.

 

N4 Pharma Market Data

Currency UK Pounds
Share Price 0.83p
Change Today 0.000p
% Change 0.00 %
52 Week High 3.07
52 Week Low 0.80
Volume 0
Shares Issued 268.78m
Market Cap £2.22m

N4 Pharma Star Ratings

Compare performance with the sector and the market.
more star ratings
Key: vs Market vs Sector
Value
35.62% below the market average35.62% below the market average35.62% below the market average35.62% below the market average35.62% below the market average
35.85% below the sector average35.85% below the sector average35.85% below the sector average35.85% below the sector average35.85% below the sector average
Value
35.62% below the market average35.62% below the market average35.62% below the market average35.62% below the market average35.62% below the market average
35.85% below the sector average35.85% below the sector average35.85% below the sector average35.85% below the sector average35.85% below the sector average
Income Not Available
Growth Not Available

N4 Pharma Dividends

No dividends found

Trades for --2024

Time Volume / Share Price
0 @ 0.000p

N4 Pharma Key Personnel

CEO Nigel Theobald

Top of Page